| Sarcoma |
2016-005252-21: Increasing the amount of pazopanib in the blood by splitting intake moments Verhogen van de hoeveelheid pazopanib in het bloed door het spreiden van inname momenten |
|
|
| Ongoing | 4 | 10 | Europe | Tablet, Votrient | Netherlands Cancer Institute, Netherlands Cancer Institute | Patients for whom pazopanib is considered standard care (advanced renal cell carcinoma and advanced soft-tissue sarcoma). Patiënten voor wie behandeling met pazopanib standaard zorg is (gevorderd renaal cel carcinoom of gevorderd weke delen sarcoom)., Patients with advanced renal cell carcinoma or advanced soft-tissue sarcoma Patiënten met nierkanker of weke delen kanker, Diseases [C] - Cancer [C04] | | | | |
2020-005751-21: Clinical Trial Extension Study with Avapritinib for Patients with Gastrointestinal Stromal Tumors |
|
|
| Not yet recruiting | 4 | 5 | Europe | Avapritinib, BLU-285, Tablet | Blueprint Medicines, Blueprint Medicines | Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Tumours, Diseases [C] - Cancer [C04] | | | | |
| Completed | 4 | 57 | Europe, Canada, US, RoW | Nilotinib, AMN107 | Novartis Pharmaceuticals | Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma | 07/23 | 07/23 | | |
NCT04033081: Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® |
|
|
| Recruiting | 4 | 100 | US | CivaSheet, brachytherapy, Intraoperative Radiation Therapy | CivaTech Oncology, TAB Clinical | Sarcoma | 12/24 | 12/28 | | |
| Active, not recruiting | 4 | 34 | Europe | Nilotinib | Novartis Pharmaceuticals | Gastrointestinal Stromal Tumors | 12/24 | 12/24 | | |
NCT04825574: Study for Patients Previously Treated in Avapritinib Clinical Trials |
|
|
| Active, not recruiting | 4 | 5 | Europe | Avapritinib, BLU-285 | Blueprint Medicines Corporation | Gastrointestinal Stromal Tumors | 08/25 | 08/25 | | |
NCT01742299 / 2012-002540-25: Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator |
|
|
| Active, not recruiting | 4 | 155 | Europe, US, RoW | imatinib mesylate, STI571 | Novartis Pharmaceuticals | GIST and CML | 04/33 | 04/33 | | |
